Chest
The Economic Burden of COPD
Section snippets
Economic Burden of Disease
Economic burden, or cost-of-illness, studies provide insight into the economic impact that illness has on society as well as on individuals and families. This approach separates economic burden into disease-attributable direct and indirect costs. The direct costs are those associated with medical management of the illness. Indirect costs are those associated with output losses and family costs as a consequence of illness (loss of work time and productivity).
Chronic bronchitis and emphysema
Trends in COPD Hospital Discharges
Expenditures for hospitalizations represent > 70% of all COPD-related medical care costs. Thus, it is important to understand the trends in hospital-related care for COPD. Using data from the National Hospital Discharge Survey, investigators at the National Center for Health Statistics evaluated the trends in COPD-related hospital discharges. The first listed diagnosis on the hospital medical record identified the discharge as being COPD related. In the United States, an estimated 553,000
Cost-Effectiveness of Pharmacologic Treatments
Rutten-van Mölken and associates24 investigated the costs and effects of adding inhaled anti-inflammatory therapy to inhaled β2-agonist therapy by analyzing data from a randomized trial of 274 adult participants aged 18 to 60 years. Patients were selected for inclusion if they met the age criteria and had been diagnosed as having moderately severe obstructive airway disease, as defined by pulmonary function criteria. Patients were eligible if they had either asthma or COPD, but most patients
Conclusion
Because COPD is highly prevalent and can be severely disabling, medical expenditures for treating COPD can represent a substantial economic burden for societies and for public and private health insurers worldwide. Nevertheless, very little economic information concerning COPD is available in the literature today. Studies of the economic burden of illness have been conducted in only a few developed countries. Although studies of direct medical-care costs may be less relevant to the developing
References (26)
- et al.
The cost of treating COPD patients with long-term oxygen therapy in a French population
Chest
(1996) - et al.
Economic analysis of respiratory rehabilitation
Chest
(1997) - et al.
Estimated growth of lung volume reduction surgery among Medicare enrollees: 1994–1996
Chest
(1998) - et al.
Lung volume reduction surgery: an analysis of hospital costs
Chest
(1998) - et al.
Economic aspects of lung volume reduction surgery
Chest
(1996) - et al.
The cost-effectiveness of lung transplantation: a pilot study
Chest
(1995) - et al.
Cost-effectiveness of lung transplantation in the Netherlands: a scenario analysis
Chest
(1998) - et al.
Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease: a three center study
Chest
(1993) - et al.
Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD
Chest
(1999) Division of Epidemiology, National Heart, Lung, and Blood Institute, 1996
Characterization of the costs of chronic obstructive pulmonary disease (COPD) in the US [abstract]
Eur Respir J
Capitation, managed care, and chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Cited by (515)
Preventing COPD Readmissions Under the Hospital Readmissions Reduction Program: How Far Have We Come?
2021, ChestCitation Excerpt :In the United States, COPD results in 923,000 ED visits and nearly 700,000 hospitalizations each year.6,7 Annual costs of treating COPD are estimated to be $50 billion,8 with 70% of this expense attributed to treating exacerbations requiring hospitalization.9 Approximately 20% of patients discharged following an exacerbation of COPD are readmitted for any reason within 30 days,10-13 making it the third leading cause of readmissions in the United States.10
Survival and health care costs after inpatient elective surgery: comparison of patients with and without chronic obstructive pulmonary disease
2023, CMAJ. Canadian Medical Association JournalImpacts of regular physical activity on hospitalisation in chronic obstructive pulmonary disease: a nationwide population-based study
2024, BMJ Open Respiratory Research